Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02859064 · ClinicalTrials.gov registry record · Phase 2
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
A Phase 2 study, sponsored by SCRI Development Innovations.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02859064 is a Phase 2 study that was terminated before completion, run by SCRI Development Innovations. The registered enrollment target is 6 participants.
The verdict
NCT02859064, a Phase 2 study, was terminated before completion, sponsored by SCRI Development Innovations.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Neuroendocrine tumors (NETs) and cancers that originate from the gastrointestinal tract can be resistant to standard chemotherapy and often metastasize to the liver. Lanreotide (Somatuline® Depot) Injection and Yttrium-90 microspheres (SIR-Spheres®) each have FDA approval to treat patients with metastatic NETs. The purpose of this study is to determine if treatment for patients with NETs can be optimized by combining these therapies.
Interventions
- DRUG Lanreotide
- DEVICE Y-90 microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-07-28 |
| Est. Completion | 2022-06-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02859064
The ClinicalTrials.gov registry entry for NCT02859064 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lanreotide is the first listed.
NCT02859064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02859064 about?
NCT02859064 is a clinical study titled "Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres". Neuroendocrine tumors (NETs) and cancers that originate from the gastrointestinal tract can be resistant to standard chemotherapy and often metastasize to the liver. Lanreotide (Somatuline® Depot) Injection and Yttrium-90 microspheres (SIR-Spheres®) each have FDA approval to treat patients with meta...
What is the current status of trial NCT02859064?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2017-07-28. Estimated completion is 2022-06-10.
What interventions are being tested in trial NCT02859064?
The interventions under investigation include: Lanreotide (DRUG), Y-90 microspheres (DEVICE).
Who is sponsoring clinical trial NCT02859064?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.